153 related articles for article (PubMed ID: 38277741)
41. Investigation of clinical application of claudin 18 isoform 2 in pancreatic ductal adenocarcinoma: A retrospective analysis of 302 chinese patients.
Zhang Z; Liu X; Zhou L; Zhang M; Liang Z
Histol Histopathol; 2022 Oct; 37(10):1031-1040. PubMed ID: 35656795
[TBL] [Abstract][Full Text] [Related]
42. Zolbetuximab plus chemotherapy for locally advanced unresectable or metastatic stomach or gastroesophageal junction cancers: a plain language summary.
Shitara K; Shah MA; Lordick F; Bang YJ; Ilson D; Cutsem EV; Enzinger P; Kim SS; Klempner SJ; Moran D; Park JW; Bhattacharya P; Ajani JA; Xu RH
Future Oncol; 2024 May; ():1-17. PubMed ID: 38861294
[TBL] [Abstract][Full Text] [Related]
43. Decreased expression of claudin-18.2 in alpha-fetoprotein-producing gastric cancer compared to conventional gastric cancer.
Weng W; Zhang M; Ni S; Tan C; Xu M; Wang X; Sun H; Wang L; Huang D; Sheng W
J Gastrointest Oncol; 2022 Jun; 13(3):1035-1045. PubMed ID: 35837176
[TBL] [Abstract][Full Text] [Related]
44. Immunological effects and activity of multiple doses of zolbetuximab in combination with zoledronic acid and interleukin-2 in a phase 1 study in patients with advanced gastric and gastroesophageal junction cancer.
Lordick F; Thuss-Patience P; Bitzer M; Maurus D; Sahin U; Türeci Ö
J Cancer Res Clin Oncol; 2023 Aug; 149(9):5937-5950. PubMed ID: 36607429
[TBL] [Abstract][Full Text] [Related]
45. Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non-small-cell lung cancer.
Micke P; Mattsson JS; Edlund K; Lohr M; Jirström K; Berglund A; Botling J; Rahnenfuehrer J; Marincevic M; Pontén F; Ekman S; Hengstler J; Wöll S; Sahin U; Türeci O
Int J Cancer; 2014 Nov; 135(9):2206-14. PubMed ID: 24710653
[TBL] [Abstract][Full Text] [Related]
46. Claudin 18.2 is a potential therapeutic target for zolbetuximab in pancreatic ductal adenocarcinoma.
Wang X; Zhang CS; Dong XY; Hu Y; Duan BJ; Bai J; Wu YY; Fan L; Liao XH; Kang Y; Zhang P; Li MY; Xu J; Mao ZJ; Liu HT; Zhang XL; Tian LF; Li EX
World J Gastrointest Oncol; 2022 Jul; 14(7):1252-1264. PubMed ID: 36051096
[TBL] [Abstract][Full Text] [Related]
47. Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy.
Cao W; Xing H; Li Y; Tian W; Song Y; Jiang Z; Yu J
Biomark Res; 2022 May; 10(1):38. PubMed ID: 35642043
[TBL] [Abstract][Full Text] [Related]
48. Evaluation and reflection on claudin 18.2 targeting therapy in advanced gastric cancer.
Zhang J; Dong R; Shen L
Chin J Cancer Res; 2020 Apr; 32(2):263-270. PubMed ID: 32410803
[TBL] [Abstract][Full Text] [Related]
49. Characterization of zolbetuximab in pancreatic cancer models.
Türeci Ӧ; Mitnacht-Kraus R; Wöll S; Yamada T; Sahin U
Oncoimmunology; 2019; 8(1):e1523096. PubMed ID: 30546962
[TBL] [Abstract][Full Text] [Related]
50. Coupling CDH17 and CLDN18 markers for comprehensive membrane-targeted detection of human gastric cancer.
Matsusaka K; Ushiku T; Urabe M; Fukuyo M; Abe H; Ishikawa S; Seto Y; Aburatani H; Hamakubo T; Kaneda A; Fukayama M
Oncotarget; 2016 Sep; 7(39):64168-64181. PubMed ID: 27580354
[TBL] [Abstract][Full Text] [Related]
51. Spatial expression of claudin 18.2 in matched primaries and metastases of tubo-ovarian carcinoma of all subtypes.
Wagner P; Gass P; Pöschke P; Eckstein M; Gloßner L; Hartmann A; Beckmann MW; Fasching PA; Ruebner M; Emons J; Erber R
Virchows Arch; 2024 Feb; ():. PubMed ID: 38326579
[TBL] [Abstract][Full Text] [Related]
52. Clinicopathological significance and immunotherapeutic outcome of claudin 18.2 expression in advanced gastric cancer: A retrospective study.
Qi C; Chong X; Zhou T; Ma M; Gong J; Zhang M; Li J; Xiao J; Peng X; Liu Z; Li Z; Shen L; Zhang X
Chin J Cancer Res; 2024 Feb; 36(1):78-89. PubMed ID: 38455365
[TBL] [Abstract][Full Text] [Related]
53. HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment.
Kunz PL; Mojtahed A; Fisher GA; Ford JM; Chang DT; Balise RR; Bangs CD; Cherry AM; Pai RK
Appl Immunohistochem Mol Morphol; 2012 Jan; 20(1):13-24. PubMed ID: 21617522
[TBL] [Abstract][Full Text] [Related]
54. Claudin 18.2 as a novel therapeutic target.
Nakayama I; Qi C; Chen Y; Nakamura Y; Shen L; Shitara K
Nat Rev Clin Oncol; 2024 May; 21(5):354-369. PubMed ID: 38503878
[TBL] [Abstract][Full Text] [Related]
55. Clinicopathological Features and Prognosis of Resected Pancreatic Ductal Adenocarcinoma Patients with Claudin-18 Overexpression.
Park S; Shin K; Kim IH; Hong T; Kim Y; Suh J; Lee M
J Clin Med; 2023 Aug; 12(16):. PubMed ID: 37629433
[TBL] [Abstract][Full Text] [Related]
56. Claudin expression in gastric adenocarcinomas: a tissue microarray study with prognostic correlation.
Resnick MB; Gavilanez M; Newton E; Konkin T; Bhattacharya B; Britt DE; Sabo E; Moss SF
Hum Pathol; 2005 Aug; 36(8):886-92. PubMed ID: 16112005
[TBL] [Abstract][Full Text] [Related]
57. Expression and prognostic analysis of CLDN18 and Claudin18.2 in lung adenocarcinoma.
Liu J; Yang H; Yin D; Jia Y; Li S; Liu Y
Pathol Res Pract; 2022 Oct; 238():154068. PubMed ID: 36007395
[TBL] [Abstract][Full Text] [Related]
58. ZO-2 Suppresses Cell Migration Mediated by a Reduction in Matrix Metalloproteinase 2 in Claudin-18-Expressing Lung Adenocarcinoma A549 Cells.
Akizuki R; Eguchi H; Endo S; Matsunaga T; Ikari A
Biol Pharm Bull; 2019; 42(2):247-254. PubMed ID: 30713254
[TBL] [Abstract][Full Text] [Related]
59. Claudin-18 is an early-stage marker of pancreatic carcinogenesis.
Tanaka M; Shibahara J; Fukushima N; Shinozaki A; Umeda M; Ishikawa S; Kokudo N; Fukayama M
J Histochem Cytochem; 2011 Oct; 59(10):942-52. PubMed ID: 21832145
[TBL] [Abstract][Full Text] [Related]
60. Claudin-18-mediated YAP activity regulates lung stem and progenitor cell homeostasis and tumorigenesis.
Zhou B; Flodby P; Luo J; Castillo DR; Liu Y; Yu FX; McConnell A; Varghese B; Li G; Chimge NO; Sunohara M; Koss MN; Elatre W; Conti P; Liebler JM; Yang C; Marconett CN; Laird-Offringa IA; Minoo P; Guan K; Stripp BR; Crandall ED; Borok Z
J Clin Invest; 2018 Mar; 128(3):970-984. PubMed ID: 29400695
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
